Meeting
2017 ASCO Annual Meeting
Allogeneic hematopoietic cell transplantation for myelofibrosis (MF) in high risk patients.
Authors
Swapna Narayana
Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI
Swapna Narayana , Saurabh Chhabra , Ravi Kishore Narra , Aniko Szabo , Mehdi Hamadani , Marcelo C. Pasquini , Nirav Shah , Parameswaran Hari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7062)
DOI
10.1200/JCO.2017.35.15_suppl.7062
Abstract #
7062
Poster Bd #
262
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Allogeneic transplantation for myelofibrosis: Benefit of dose intensity.
First Author: Uday R. Popat
Poster
2014 ASCO Annual Meeting
Treatment patterns, mortality, and costs of care in unfit patients (pts) with relapsed chronic lymphocytic leukemia (CLL).
First Author: Helen Varker
Poster
2024 ASCO Annual Meeting
Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.
First Author: Justin M. Watts
Poster
2023 ASCO Annual Meeting
Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.
First Author: Uday R. Popat